{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T08:24:28Z","timestamp":1794817468489,"version":"4.9.1"},"publisher-location":"Cham","reference-count":143,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783031972416","type":"print"},{"value":"9783031972423","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-3-031-97242-3_10","type":"book-chapter","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T20:23:27Z","timestamp":1755894207000},"page":"187-220","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Role of Immunotherapy in Ovarian Cancer: Advances, Challenges, and Future Perspectives"],"prefix":"10.1007","author":[{"given":"Pankaj","family":"Garg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gargi","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhika","family":"Pareek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajaz","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TingTing","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deric","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6415-8160","authenticated-orcid":false,"given":"Sharad S.","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"key":"10_CR1","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2147\/IJWH.S197604","volume":"11","author":"Z Momenimovahed","year":"2019","unstructured":"Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Women\u2019s Health. 2019;11:287\u201399.","journal-title":"Int J Women\u2019s Health"},{"key":"10_CR2","doi-asserted-by":"publisher","unstructured":"Elias KM, Guo J, Bast RC Jr. Early detection of ovarian cancer. Hematol Oncol Clin North Am. 2018;32(6):903\u201314. Marth C, Abreu MH, Andersen KK, et al. Real-life data on treatment and outcomes in advanced ovarian cancer: an observational, multinational cohort study (RESPONSE trial). Cancer. 2022;128(16):3080\u201389. https:\/\/doi.org\/10.1002\/cncr.34350.","DOI":"10.1002\/cncr.34350"},{"key":"10_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2024.101017","volume":"44","author":"WK Ho","year":"2024","unstructured":"Ho WK, Hassan NT, Yoon SY, et al. Age-specific breast, and ovarian cancer risks associated with germline BRCA1 or BRCA2 pathogenic variants\u2014an Asian study of 572 families. Lancet Reg Health West Pac. 2024;44:101017. Published 2024 Feb 5. https:\/\/doi.org\/10.1016\/j.lanwpc.2024.101017.","journal-title":"Lancet Reg Health West Pac"},{"issue":"11","key":"10_CR4","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1093\/jnci\/djae164","volume":"116","author":"G Zheng","year":"2024","unstructured":"Zheng G, Baandrup L, Wang J, Hertzum-Larsen R, Hannibal CG, Faber MT, Sundstr\u00f6m K, Kj\u00e6r SK. Ovarian cancer risk factors in relation to family history. J Natl Cancer Inst. 2024;116(11):1767\u201374. https:\/\/doi.org\/10.1093\/jnci\/djae164.","journal-title":"J Natl Cancer Inst"},{"issue":"16","key":"10_CR5","doi-asserted-by":"publisher","first-page":"7018","DOI":"10.1002\/cam4.2560","volume":"8","author":"A Chandra","year":"2019","unstructured":"Chandra A, Pius C, Nabeel M, Nair M, Vishwanatha JK, Ahmad S, Basha R. Ovarian cancer: current status and strategies for improving therapeutic outcomes. Cancer Med. 2019;8(16):7018\u201331. https:\/\/doi.org\/10.1002\/cam4.2560.","journal-title":"Cancer Med"},{"issue":"14","key":"10_CR6","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.3390\/cancers15143556","volume":"15","author":"S Quesada","year":"2023","unstructured":"Quesada S, Thomas QD, Colombo PE, Fiteni F. Optimal first-line medico-surgical strategy in ovarian cancers: are we there yet? Cancer. 2023;15(14):3556. https:\/\/doi.org\/10.3390\/cancers15143556.","journal-title":"Cancer"},{"key":"10_CR7","doi-asserted-by":"publisher","unstructured":"Pinelli C, Guerrisi R, Brusadelli C, Artuso V, Majd HS, Bogani G, Ghezzi F, Casarin J. Interval debulking surgery for advanced ovarian cancer: when how and why? Gynecol Pelvic Med. 2021;4 https:\/\/doi.org\/10.21037\/gpm-20-61.","DOI":"10.21037\/gpm-20-61"},{"issue":"4","key":"10_CR8","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1200\/JCO.1998.16.4.1494","volume":"16","author":"PG Rose","year":"1998","unstructured":"Rose PG, Fusco N, Fluellen L, Rodriguez M. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol. 1998;16(4):1494\u20137. https:\/\/doi.org\/10.1200\/JCO.1998.16.4.1494.","journal-title":"J Clin Oncol"},{"issue":"7","key":"10_CR9","doi-asserted-by":"publisher","first-page":"CD005343","DOI":"10.1002\/14651858.CD005343.pub6","volume":"7","author":"SL Coleridge","year":"2021","unstructured":"Coleridge SL, Bryant A, Kehoe S, Morrison J. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev. 2021;7(7):CD005343. https:\/\/doi.org\/10.1002\/14651858.CD005343.pub6.","journal-title":"Cochrane Database Syst Rev"},{"key":"10_CR10","doi-asserted-by":"publisher","first-page":"1441222","DOI":"10.3389\/fonc.2024.1441222","volume":"14","author":"Y Xie","year":"2024","unstructured":"Xie Y, Xiao D, Li D, Peng M, Peng W, Duan H, Yang X. Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer. Front Oncol. 2024;14:1441222. https:\/\/doi.org\/10.3389\/fonc.2024.1441222.","journal-title":"Front Oncol"},{"issue":"17","key":"10_CR11","doi-asserted-by":"publisher","first-page":"13618","DOI":"10.3390\/ijms241713618","volume":"24","author":"HY Choi","year":"2023","unstructured":"Choi HY, Chang JE. Targeted therapy for cancers: from ongoing clinical trials to FDA-approved drugs. Int J Mol Sci. 2023;24(17):13618. https:\/\/doi.org\/10.3390\/ijms241713618.","journal-title":"Int J Mol Sci"},{"key":"10_CR12","doi-asserted-by":"publisher","first-page":"1179299X1986081","DOI":"10.1177\/1179299X19860815","volume":"11","author":"R Pokhriyal","year":"2019","unstructured":"Pokhriyal R, Hariprasad R, Kumar L, Hariprasad G. Chemotherapy resistance in advanced ovarian cancer patients. Biomarkers Cancer. 2019;11:1179299X19860815. https:\/\/doi.org\/10.1177\/1179299X19860815.","journal-title":"Biomarkers Cancer"},{"key":"10_CR13","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3390\/medicina59030544","volume":"59","author":"A Havasi","year":"2023","unstructured":"Havasi A, Cainap SS, Havasi AT, Cainap C. Ovarian cancer\u2014insights into platinum resistance and overcoming it. Medicina. 2023;59:544. https:\/\/doi.org\/10.3390\/medicina59030544.","journal-title":"Medicina"},{"issue":"1","key":"10_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/cancers11010119","volume":"11","author":"G Damia","year":"2019","unstructured":"Damia G, Broggini M. Platinum resistance in ovarian cancer: role of DNA repair. Cancer. 2019;11(1):119. https:\/\/doi.org\/10.3390\/cancers11010119.","journal-title":"Cancer"},{"issue":"11","key":"10_CR15","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1517\/13543784.2010.515585","volume":"19","author":"K Matsuo","year":"2010","unstructured":"Matsuo K, Lin YG, Roman LD, Sood AK. Overcoming platinum resistance in ovarian carcinoma. Expert Opin Investig Drugs. 2010;19(11):1339\u201354. https:\/\/doi.org\/10.1517\/13543784.2010.515585.","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"10_CR16","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","volume":"10","author":"U Anand","year":"2022","unstructured":"Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, De Falco V, Upadhyay A, Kandimalla R, Chaudhary A, Dhanjal JK, Dewanjee S, Vallamkondu J, P\u00e9rez de la Lastra JM. Cancer chemotherapy and beyond: current status, drug candidates, associated risks, and progress in targeted therapeutics. Genes Dis. 2022;10(4):1367\u2013401. https:\/\/doi.org\/10.1016\/j.gendis.2022.02.007.","journal-title":"Genes Dis"},{"key":"10_CR17","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.pharmthera.2017.08.012","volume":"182","author":"M Li","year":"2018","unstructured":"Li M, Kroetz DL. Bevacizumab-induced hypertension: clinical presentation and molecular understanding. Pharmacol Ther. 2018;182:152\u201360. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.08.012.","journal-title":"Pharmacol Ther"},{"issue":"10","key":"10_CR18","doi-asserted-by":"publisher","first-page":"djx144","DOI":"10.1093\/jnci\/djx144","volume":"109","author":"JA Doherty","year":"2017","unstructured":"Doherty JA, Jensen A, Kelemen LE, Pearce CL, Poole E, Schildkraut JM, Terry KL, Tworoger SS, Webb PM, Wentzensen N. Current gaps in ovarian cancer epidemiology: the need for new population-based research. J Natl Cancer Inst. 2017;109(10):djx144. https:\/\/doi.org\/10.1093\/jnci\/djx144.","journal-title":"J Natl Cancer Inst"},{"key":"10_CR19","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/497429","volume":"2010","author":"K Ushijima","year":"2010","unstructured":"Ushijima K. Treatment for recurrent ovarian cancer-at first relapse. J Oncol. 2010;2010:497429. https:\/\/doi.org\/10.1155\/2010\/497429.","journal-title":"J Oncol"},{"key":"10_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s44294-024-00010-6","volume":"2","author":"K Kleinmanns","year":"2024","unstructured":"Kleinmanns K, Bj\u00f8rge L. Enhancing precision oncology in high-grade serous carcinoma: the emerging role of antibody-based therapies. npj Womens Health. 2024;2:7. https:\/\/doi.org\/10.1038\/s44294-024-00010-6.","journal-title":"npj Womens Health"},{"issue":"1","key":"10_CR21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ygyno.2016.02.023","volume":"141","author":"B Winterhoff","year":"2016","unstructured":"Winterhoff B, Hamidi H, Wang C, Kalli KR, Fridley BL, Dering J, Chen HW, Cliby WA, Wang HJ, Dowdy S, Gostout BS, Keeney GL, Goode EL, Konecny GE. Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures. Gynecol Oncol. 2016;141(1):95\u2013100. https:\/\/doi.org\/10.1016\/j.ygyno.2016.02.023.","journal-title":"Gynecol Oncol"},{"issue":"10","key":"10_CR22","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1038\/s12276-022-00864-3","volume":"54","author":"HY Min","year":"2022","unstructured":"Min HY, Lee HY. Molecular targeted therapy for anticancer treatment. Exp Mol Med. 2022;54(10):1670\u201394. https:\/\/doi.org\/10.1038\/s12276-022-00864-3.","journal-title":"Exp Mol Med"},{"key":"10_CR23","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.3390\/cimb45020081","volume":"45","author":"H Yoon","year":"2023","unstructured":"Yoon H, Kim A, Jang H. Immunotherapeutic approaches in ovarian cancer. Curr Issues Mol Biol. 2023;45:1233\u201349. https:\/\/doi.org\/10.3390\/cimb45020081.","journal-title":"Curr Issues Mol Biol"},{"key":"10_CR24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","volume":"9","author":"B Liu","year":"2024","unstructured":"Liu B, Zhou H, Tan L, et al. Exploring treatment options in cancer: tumor treatment strategies. Sig Transduct Target Ther. 2024;9:175. https:\/\/doi.org\/10.1038\/s41392-024-01856-7.","journal-title":"Sig Transduct Target Ther"},{"key":"10_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40364-024-00599-5","volume":"12","author":"K Yang","year":"2024","unstructured":"Yang K, Lu R, Mei J, et al. The war between the immune system and the tumor\u2014using immune biomarkers as tracers. Biomark Res. 2024;12:51. https:\/\/doi.org\/10.1186\/s40364-024-00599-5.","journal-title":"Biomark Res"},{"key":"10_CR26","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","volume":"14","author":"S Zhu","year":"2021","unstructured":"Zhu S, Zhang T, Zheng L, et al. Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol. 2021;14:156. https:\/\/doi.org\/10.1186\/s13045-021-01164-5.","journal-title":"J Hematol Oncol"},{"key":"10_CR27","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.3389\/fimmu.2019.02965","volume":"10","author":"P Dobosz","year":"2019","unstructured":"Dobosz P, Dzieci\u0105tkowski T. The intriguing history of cancer immunotherapy. Front Immunol. 2019;10:2965. https:\/\/doi.org\/10.3389\/fimmu.2019.02965.","journal-title":"Front Immunol"},{"key":"10_CR28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12943-023-01826-7","volume":"22","author":"S Muhammad","year":"2023","unstructured":"Muhammad S, Fan T, Hai Y, et al. Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies. Mol Cancer. 2023;22:121. https:\/\/doi.org\/10.1186\/s12943-023-01826-7.","journal-title":"Mol Cancer"},{"issue":"5","key":"10_CR29","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, Ladwa R, O\u2019Byrne K, Kulasinghe A. Immune checkpoint inhibitors in cancer therapy. Curr Oncol (Toronto, Ont). 2022;29(5):3044\u201360. https:\/\/doi.org\/10.3390\/curroncol29050247.","journal-title":"Curr Oncol (Toronto, Ont)"},{"key":"10_CR30","doi-asserted-by":"publisher","first-page":"1212444","DOI":"10.3389\/fimmu.2023.1212444","volume":"14","author":"E Tassi","year":"2023","unstructured":"Tassi E, Bergamini A, Wignall J, Sant\u2019Angelo M, Brunetto E, Balestrieri C, Redegalli M, Potenza A, Abbati D, Manfredi F, Cangi MG, Magliacane G, Scalisi F, Ruggiero E, Maffia MC, Trippitelli F, Rabaiotti E, Cioffi R, Bocciolone L, Candotti G, Bonini C. Epithelial ovarian cancer is infiltrated by activated effector T cells co-expressing CD39, PD-1, TIM-3, CD137 and interacting with cancer cells and myeloid cells. Front Immunol. 2023;14:1212444. https:\/\/doi.org\/10.3389\/fimmu.2023.1212444.","journal-title":"Front Immunol"},{"issue":"11","key":"10_CR31","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1007\/s00262-023-03529-w","volume":"72","author":"SS Mun","year":"2023","unstructured":"Mun SS, Meyerberg J, Peraro L, Korontsvit T, Gardner T, Malviya M, Kyi C, O\u2019Cearbhaill RE, Liu C, Dao T, Scheinberg DA. Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1. Cancer Immunol Immunother. 2023;72(11):3773\u201386. https:\/\/doi.org\/10.1007\/s00262-023-03529-w.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10_CR32","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s12967-024-05174-y","volume":"22","author":"J Guo","year":"2024","unstructured":"Guo J, Zeng X, Zhu Y, Yang D, Zhao X. Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer. J Transl Med. 2024;22(1):367. https:\/\/doi.org\/10.1186\/s12967-024-05174-y.","journal-title":"J Transl Med"},{"key":"10_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116646","volume":"231","author":"P Garg","year":"2025","unstructured":"Garg P, Pareek S, Kulkarni P, Horne D, Salgia R, Singhal SS. Exploring the potential of TGF\u03b2 as a diagnostic marker and therapeutic target against cancer. Biochem Pharmacol. 2025;231:116646. https:\/\/doi.org\/10.1016\/j.bcp.2024.116646.","journal-title":"Biochem Pharmacol"},{"key":"10_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116498","volume":"229","author":"P Garg","year":"2024","unstructured":"Garg P, Ramisetty SK, Raghu Subbalakshmi A, Krishna BM, Pareek S, Mohanty A, Kulkarni P, Horne D, Salgia R, Singhal SS. Gynecological cancer tumor microenvironment: unveiling cellular complexity and therapeutic potential. Biochem Pharmacol. 2024;229:116498. https:\/\/doi.org\/10.1016\/j.bcp.2024.116498.","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10_CR35","doi-asserted-by":"publisher","first-page":"182","DOI":"10.4103\/ijmpo.ijmpo_73_16","volume":"38","author":"CK Bose","year":"2017","unstructured":"Bose CK. Immune checkpoint blockers and ovarian cancer. Indian J Med Paediatr Oncol. 2017;38(2):182\u20139. https:\/\/doi.org\/10.4103\/ijmpo.ijmpo_73_16.","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"3","key":"10_CR36","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han Y, Liu D, Li L. PD-1\/PD-L1 pathway: current research in cancer. Am J Cancer Res. 2020;10(3):727\u201342.","journal-title":"Am J Cancer Res"},{"issue":"18","key":"10_CR37","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.3390\/cancers14184344","volume":"14","author":"D Fanale","year":"2022","unstructured":"Fanale D, Dimino A, Pedone E, Brando C, Corsini LR, Filorizzo C, Fiorino A, Lisanti MC, Magrin L, Randazzo U, Bazan Russo TD, Russo A, Bazan V. Prognostic and predictive role of tumor-infiltrating lymphocytes (TILs) in ovarian cancer. Cancer. 2022;14(18):4344. https:\/\/doi.org\/10.3390\/cancers14184344.","journal-title":"Cancer"},{"key":"10_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116930","volume":"177","author":"W Zhang","year":"2024","unstructured":"Zhang W, Wang M, Ji C, Liu X, Gu B, Dong T. Macrophage polarization in the tumor microenvironment: emerging roles and therapeutic potentials. Biomed Pharmacother. 2024;177:116930. https:\/\/doi.org\/10.1016\/j.biopha.2024.116930.","journal-title":"Biomed Pharmacother"},{"key":"10_CR39","doi-asserted-by":"publisher","first-page":"1328651","DOI":"10.3389\/fimmu.2023.1328651","volume":"14","author":"F Blanc-Durand","year":"2023","unstructured":"Blanc-Durand F, Clemence Wei Xian L, Tan DSP. Targeting the immune microenvironment for ovarian cancer therapy. Front Immunol. 2023;14:1328651. https:\/\/doi.org\/10.3389\/fimmu.2023.1328651.","journal-title":"Front Immunol"},{"issue":"3","key":"10_CR40","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s10555-021-09976-0","volume":"40","author":"MZ Wojtukiewicz","year":"2021","unstructured":"Wojtukiewicz MZ, Rek MM, Karpowicz K, G\u00f3rska M, Polity\u0144ska B, Wojtukiewicz AM, Moniuszko M, Radziwon P, Tucker SC, Honn KV. Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer Metastasis Rev. 2021;40(3):949\u201382. https:\/\/doi.org\/10.1007\/s10555-021-09976-0.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"10_CR41","doi-asserted-by":"publisher","first-page":"008","DOI":"10.24875\/RIC.20000341","volume":"73","author":"L C\u00f3rdova-Bahena","year":"2020","unstructured":"C\u00f3rdova-Bahena L, Velasco-Vel\u00e1zquez MA. Anti-PD-1 and anti-PD-L1 antibodies as immunotherapy against cancer: a structural perspective. Rev Investig Clin. 2020;73(1):008\u201316. https:\/\/doi.org\/10.24875\/RIC.20000341.","journal-title":"Rev Investig Clin"},{"issue":"13","key":"10_CR42","doi-asserted-by":"publisher","first-page":"10859","DOI":"10.3390\/ijms241310859","volume":"24","author":"A Paw\u0142owska","year":"2023","unstructured":"Paw\u0142owska A, Rekowska A, Kury\u0142o W, Pa\u0144czyszyn A, Kotarski J, Wertel I. Current understanding on why ovarian cancer is resistant to immune checkpoint inhibitors. Int J Mol Sci. 2023;24(13):10859. https:\/\/doi.org\/10.3390\/ijms241310859.","journal-title":"Int J Mol Sci"},{"key":"10_CR43","doi-asserted-by":"publisher","first-page":"853","DOI":"10.37349\/ei.2024.00177","volume":"4","author":"L Zhao","year":"2024","unstructured":"Zhao L, Zhai Y, Niu G. Research progress of immune checkpoint inhibitors in ovarian cancer. Explor Immunol. 2024;4:853\u201370. https:\/\/doi.org\/10.37349\/ei.2024.00177.","journal-title":"Explor Immunol"},{"issue":"7","key":"10_CR44","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","volume":"30","author":"UA Matulonis","year":"2019","unstructured":"Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, Raspagliesi F, Sonke GS, Birrer M, Provencher DM, Sehouli J, Colombo N, Gonz\u00e1lez-Mart\u00edn A, Oaknin A, Ottevanger PB, Rudaitis V, Katchar K, Wu H, Keefe S, Ruman J, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019;30(7):1080\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdz135.","journal-title":"Ann Oncol"},{"issue":"6","key":"10_CR45","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.3390\/biomedicines12061291","volume":"12","author":"MD Velimirovici","year":"2024","unstructured":"Velimirovici MD, Feier CVI, Vonica RC, Faur AM, Muntean C. Efficacy and safety of atezolizumab as a PD-L1 inhibitor in the treatment of cervical cancer: a systematic review. Biomedicine. 2024;12(6):1291. https:\/\/doi.org\/10.3390\/biomedicines12061291.","journal-title":"Biomedicine"},{"issue":"6","key":"10_CR46","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3390\/pharmaceutics16060732","volume":"16","author":"B Khan","year":"2024","unstructured":"Khan B, Qahwaji RM, Alfaifi MS, Mobashir M. Nivolumab and ipilimumab acting as tormentors of advanced tumors by unleashing immune cells and associated collateral damage. Pharmaceutics. 2024;16(6):732. https:\/\/doi.org\/10.3390\/pharmaceutics16060732.","journal-title":"Pharmaceutics"},{"key":"10_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.577869","volume":"11","author":"C Yang","year":"2020","unstructured":"Yang C, Xia BR, Zhang ZC, Zhang YJ, Lou G, Jin WL. Immunotherapy for ovarian cancer: adjuvant, combination, and neoadjuvant. Front Immunol. 2020;11:577869. https:\/\/doi.org\/10.3389\/fimmu.2020.577869.","journal-title":"Front Immunol"},{"issue":"21","key":"10_CR48","doi-asserted-by":"publisher","first-page":"5332","DOI":"10.3390\/cancers14215332","volume":"14","author":"D Hudry","year":"2022","unstructured":"Hudry D, Le Guellec S, Meignan S, B\u00e9court S, Pasquesoone C, El Hajj H, Mart\u00ednez-G\u00f3mez C, Leblanc \u00c9, Narducci F, Ladoire S. Tumor-infiltrating lymphocytes (TILs) in epithelial ovarian cancer: heterogeneity, prognostic impact, and relationship with immune checkpoints. Cancer. 2022;14(21):5332. https:\/\/doi.org\/10.3390\/cancers14215332.","journal-title":"Cancer"},{"issue":"5","key":"10_CR49","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","volume":"44","author":"AC Anderson","year":"2016","unstructured":"Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989\u20131004. https:\/\/doi.org\/10.1016\/j.immuni.2016.05.001.","journal-title":"Immunity"},{"key":"10_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.559161","volume":"11","author":"H Varayathu","year":"2021","unstructured":"Varayathu H, Sarathy V, Thomas BE, Mufti SS, Naik R. Combination strategies to augment immune check point inhibitors efficacy\u2014implications for translational research. Front Oncol. 2021;11:559161. https:\/\/doi.org\/10.3389\/fonc.2021.559161.","journal-title":"Front Oncol"},{"issue":"4","key":"10_CR51","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrc2355","volume":"8","author":"SA Rosenberg","year":"2008","unstructured":"Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfers: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8(4):299\u2013308. https:\/\/doi.org\/10.1038\/nrc2355.","journal-title":"Nat Rev Cancer"},{"key":"10_CR52","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12916-021-02006-4","volume":"19","author":"S Wang","year":"2021","unstructured":"Wang S, Sun J, Chen K, et al. Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors. BMC Med. 2021;19:140. https:\/\/doi.org\/10.1186\/s12916-021-02006-4.","journal-title":"BMC Med"},{"issue":"2","key":"10_CR53","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","volume":"6","author":"A Morello","year":"2016","unstructured":"Morello A, Sadelain M, Adusumilli PS. Mesothelin-targeted CARs: driving T cells to solid tumors. Cancer Discov. 2016;6(2):133\u201346. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0583.","journal-title":"Cancer Discov"},{"issue":"11","key":"10_CR54","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1158\/2326-6066.CIR-21-0269","volume":"9","author":"U Greenbaum","year":"2021","unstructured":"Greenbaum U, Dumbrava EI, Biter AB, Haymaker CL, Hong DS. Engineered T-cell receptor T cells for cancer immunotherapy. Cancer Immunol Res. 2021;9(11):1252\u201361. https:\/\/doi.org\/10.1158\/2326-6066.CIR-21-0269.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"10_CR55","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00262-022-03238-w","volume":"72","author":"J Chen","year":"2023","unstructured":"Chen J, Hu J, Gu L, Ji F, Zhang F, Zhang M, Li J, Chen Z, Jiang L, Zhang Y, Shi R, Ma L, Jia S, Zhang Y, Zhang Q, Liang J, Yao S, Hu Z, Guo Z. Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer. Cancer Immunol Immunother. 2023;72(2):409\u201325. https:\/\/doi.org\/10.1007\/s00262-022-03238-w.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"10_CR56","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22(2):85\u201396. https:\/\/doi.org\/10.1038\/s41577-021-00547-6.","journal-title":"Nat Rev Immunol"},{"key":"10_CR57","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.3390\/jcm13113202","volume":"13","author":"MS Choudhery","year":"2024","unstructured":"Choudhery MS, Arif T, Mahmood R, Harris DT. CAR-T-cell-based cancer immunotherapies: potentials, limitations, and future prospects. J Clin Med. 2024;13:3202. https:\/\/doi.org\/10.3390\/jcm13113202.","journal-title":"J Clin Med"},{"issue":"11","key":"10_CR58","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","volume":"31","author":"L Tang","year":"2023","unstructured":"Tang L, Pan S, Wei X, Xu X, Wei Q. Arming CAR-T cells with cytokines and more: innovations in the fourth-generation CAR-T development. Mol Ther. 2023;31(11):3146\u201362. https:\/\/doi.org\/10.1016\/j.ymthe.2023.09.021.","journal-title":"Mol Ther"},{"key":"10_CR59","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s00262-024-03793-4","volume":"73","author":"S Matsueda","year":"2024","unstructured":"Matsueda S, Chen L, Li H, et al. Recent clinical researches and technological development in TIL therapy. Cancer Immunol Immunother. 2024;73:232. https:\/\/doi.org\/10.1007\/s00262-024-03793-4.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189233","volume":"1880","author":"P Garg","year":"2025","unstructured":"Garg P, Singhal G, Pareek S, Kulkarni P, Horne D, Nath A, Salgia R, Singhal SS. Unveiling the potential of gene editing techniques in revolutionizing cancer treatment: a comprehensive overview. Biochim Biophys Acta Rev Cancer. 2025;1880(1):189233. https:\/\/doi.org\/10.1016\/j.bbcan.2024.189233.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"3","key":"10_CR61","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3390\/diagnostics11030465","volume":"11","author":"GA Atallah","year":"2021","unstructured":"Atallah GA, Abd Aziz NH, Teik CK, Shafiee MN, Kampan NC. New predictive biomarkers for ovarian cancer. Diagnostics. 2021;11(3):465. https:\/\/doi.org\/10.3390\/diagnostics11030465.","journal-title":"Diagnostics"},{"issue":"4","key":"10_CR62","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3390\/vaccines8040657","volume":"8","author":"S Chow","year":"2020","unstructured":"Chow S, Berek JS, Dorigo O. Development of therapeutic vaccines for ovarian cancer. Vaccine. 2020;8(4):657. https:\/\/doi.org\/10.3390\/vaccines8040657.","journal-title":"Vaccine"},{"key":"10_CR63","doi-asserted-by":"publisher","first-page":"1255799","DOI":"10.3389\/fimmu.2023.1255799","volume":"14","author":"H Zhou","year":"2023","unstructured":"Zhou H, Ma Y, Liu F, Li B, Qiao D, Ren P, Wang M. Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment. Front Immunol. 2023;14:1255799. https:\/\/doi.org\/10.3389\/fimmu.2023.1255799.","journal-title":"Front Immunol"},{"key":"10_CR64","doi-asserted-by":"publisher","first-page":"9749363","DOI":"10.1155\/2022\/9749363","volume":"2022","author":"N Abd-Aziz","year":"2022","unstructured":"Abd-Aziz N, Poh CL. Development of peptide-based vaccines for cancer. J Oncol. 2022;2022:9749363. https:\/\/doi.org\/10.1155\/2022\/9749363.","journal-title":"J Oncol"},{"key":"10_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.953887","volume":"10","author":"C Saha","year":"2022","unstructured":"Saha C, Bojdo J, Dunne NJ, Duary RK, Buckley N, McCarthy HO. Nucleic acid vaccination strategies for ovarian cancer. Front Bioeng Biotechnol. 2022;10:953887. https:\/\/doi.org\/10.3389\/fbioe.2022.953887.","journal-title":"Front Bioeng Biotechnol"},{"issue":"2","key":"10_CR66","doi-asserted-by":"publisher","first-page":"443","DOI":"10.4049\/jimmunol.1701024","volume":"200","author":"PM Santos","year":"2018","unstructured":"Santos PM, Butterfield LH. Dendritic cell-based cancer vaccines. J Immunol. 2018;200(2):443\u20139. https:\/\/doi.org\/10.4049\/jimmunol.1701024.","journal-title":"J Immunol"},{"issue":"17","key":"10_CR67","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.3390\/cells12172147","volume":"12","author":"KW Lee","year":"2023","unstructured":"Lee KW, Yam JWP, Mao X. Dendritic cell vaccines: a shift from conventional approach to new generations. Cells. 2023;12(17):2147. https:\/\/doi.org\/10.3390\/cells12172147.","journal-title":"Cells"},{"issue":"10","key":"10_CR68","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1517\/13543784.2013.822066","volume":"22","author":"J Bedke","year":"2013","unstructured":"Bedke J, Stenzl A. IMA901: a peptide vaccine in renal cell carcinoma. Expert Opin Investig Drugs. 2013;22(10):1329\u201336. https:\/\/doi.org\/10.1517\/13543784.2013.822066.","journal-title":"Expert Opin Investig Drugs"},{"issue":"10008","key":"10_CR69","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","volume":"386","author":"CL Trimble","year":"2015","unstructured":"Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, Edwards L, Parker RL, Denny L, Giffear M, Brown AS, Marcozzi-Pierce K, Shah D, Slager AM, Sylvester AJ, Khan A, Broderick KE, Juba RJ, Herring TA, Boyer J, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet. 2015;386(10008):2078\u201388. https:\/\/doi.org\/10.1016\/S0140-6736(15)00239-1.","journal-title":"Lancet"},{"issue":"1","key":"10_CR70","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","volume":"8","author":"T Fan","year":"2023","unstructured":"Fan T, Zhang M, Yang J, Zhu Z, Cao W, Dong C. Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduct Target Ther. 2023;8(1):450. https:\/\/doi.org\/10.1038\/s41392-023-01674-3.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"10_CR71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155189","volume":"11","author":"SD Martin","year":"2016","unstructured":"Martin SD, Brown SD, Wick DA, Nielsen JS, Kroeger DR, Twumasi-Boateng K, Holt RA, Nelson BH. Low mutation burden in ovarian cancer may limit the utility of neoantigen-targeted vaccines. PLoS One. 2016;11(5):e0155189. https:\/\/doi.org\/10.1371\/journal.pone.0155189.","journal-title":"PLoS One"},{"issue":"6","key":"10_CR72","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3390\/vaccines9060579","volume":"9","author":"M Van Tilbeurgh","year":"2021","unstructured":"Van Tilbeurgh M, Lemdani K, Beignon AS, Chapon C, Tchitchek N, Cheraitia L, Marcos Lopez E, Pascal Q, Le Grand R, Maisonnasse P, Manet C. Predictive markers of immunogenicity and efficacy for human vaccines. Vaccine. 2021;9(6):579. https:\/\/doi.org\/10.3390\/vaccines9060579.","journal-title":"Vaccine"},{"issue":"4","key":"10_CR73","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1158\/2326-6066.CIR-14-0015","volume":"2","author":"EA Chiocca","year":"2014","unstructured":"Chiocca EA, Rabkin SD. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res. 2014;2(4):295\u2013300. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0015.","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"10_CR74","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1596006","volume":"8","author":"ME Davola","year":"2019","unstructured":"Davola ME, Mossman KL. Oncolytic viruses: how \u201clytic\u201d must they be for therapeutic efficacy? Onco Targets Ther. 2019;8(6):e1581528. https:\/\/doi.org\/10.1080\/2162402X.2019.1596006.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"10_CR75","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41392-022-00951-x","volume":"7","author":"Y Tian","year":"2022","unstructured":"Tian Y, Xie D, Yang L. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. Signal Transduct Target Ther. 2022;7(1):117. https:\/\/doi.org\/10.1038\/s41392-022-00951-x.","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"10_CR76","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1586\/14737140.2015.1115725","volume":"15","author":"KJ Harrington","year":"2015","unstructured":"Harrington KJ, Puzanov I, Hecht JR, Hodi FS, Szabo Z, Murugappan S, Kaufman HL. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy. Expert Rev Anticancer Ther. 2015;15(12):1389\u2013403. https:\/\/doi.org\/10.1586\/14737140.2015.1115725.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"19","key":"10_CR77","doi-asserted-by":"publisher","first-page":"10522","DOI":"10.3390\/ijms221910522","volume":"22","author":"K Mantwill","year":"2021","unstructured":"Mantwill K, Klein FG, Wang D, Hindupur SV, Ehrenfeld M, Holm PS, Nawroth R. Concepts in oncolytic adenovirus therapy. Int J Mol Sci. 2021;22(19):10522. https:\/\/doi.org\/10.3390\/ijms221910522.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10_CR78","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.3390\/cancers12113219","volume":"12","author":"L M\u00fcller","year":"2020","unstructured":"M\u00fcller L, Berkeley R, Barr T, Ilett E, Errington-Mais F. Past, present and future of oncolytic reovirus. Cancer. 2020;12(11):3219. https:\/\/doi.org\/10.3390\/cancers12113219.","journal-title":"Cancer"},{"key":"10_CR79","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s40164-022-00338-2","volume":"11","author":"S Cousin","year":"2022","unstructured":"Cousin S, Toulmonde M, Kind M, et al. Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer. Exp Hematol Oncol. 2022;11:104. https:\/\/doi.org\/10.1186\/s40164-022-00338-2.","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"10_CR80","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3390\/cancers13030544","volume":"13","author":"CE Engeland","year":"2021","unstructured":"Engeland CE, Ungerechts G. Measles virus as an oncolytic immunotherapy. Cancer. 2021;13(3):544. https:\/\/doi.org\/10.3390\/cancers13030544.","journal-title":"Cancer"},{"key":"10_CR81","doi-asserted-by":"publisher","first-page":"1450203","DOI":"10.3389\/fphar.2024.1450203","volume":"15","author":"ZS Yin","year":"2024","unstructured":"Yin ZS, Wang Z. Strategies for engineering oncolytic viruses to enhance cancer immunotherapy. Front Pharmacol. 2024;15:1450203. https:\/\/doi.org\/10.3389\/fphar.2024.1450203.","journal-title":"Front Pharmacol"},{"issue":"6","key":"10_CR82","first-page":"1696","volume":"62","author":"K Hirasawa","year":"2002","unstructured":"Hirasawa K, Nishikawa SG, Norman KL, Alain T, Kossakowska A, Lee PW. Oncolytic reovirus against ovarian and colon cancer. Cancer Res. 2002;62(6):1696\u2013701.","journal-title":"Cancer Res"},{"issue":"6","key":"10_CR83","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.3390\/cancers13061383","volume":"13","author":"PF Ferrucci","year":"2021","unstructured":"Ferrucci PF, Pala L, Conforti F, Cocorocchio E. Talimogene laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma. Cancer. 2021;13(6):1383. https:\/\/doi.org\/10.3390\/cancers13061383.","journal-title":"Cancer"},{"issue":"5","key":"10_CR84","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/s41416-023-02344-5","volume":"129","author":"D Mahalingam","year":"2023","unstructured":"Mahalingam D, Chen S, Xie P, Loghmani H, Heineman T, Kalyan A, Kircher S, Helenowski IB, Mi X, Maurer V, Coffey M, Mulcahy M, Benson A, Zhang B. Combination of pembrolizumab and pelareorep promotes anti-tumour immunity in advanced pancreatic adenocarcinoma (PDAC). Br J Cancer. 2023;129(5):782\u201390. https:\/\/doi.org\/10.1038\/s41416-023-02344-5.","journal-title":"Br J Cancer"},{"issue":"13","key":"10_CR85","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.3390\/cancers16132478","volume":"16","author":"P Garg","year":"2024","unstructured":"Garg P, Malhotra J, Kulkarni P, Horne D, Salgia R, Singhal SS. Emerging therapeutic strategies to overcome drug resistance in cancer cells. Cancer. 2024;16(13):2478. https:\/\/doi.org\/10.3390\/cancers16132478.","journal-title":"Cancer"},{"issue":"9","key":"10_CR86","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrd4663","volume":"14","author":"HL Kaufman","year":"2015","unstructured":"Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nature reviews. Drug Des Discov. 2015;14(9):642\u201362. https:\/\/doi.org\/10.1038\/nrd4663.","journal-title":"Drug Des Discov"},{"key":"10_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.820128","volume":"12","author":"A Nikolaidi","year":"2022","unstructured":"Nikolaidi A, Fountzilas E, Fostira F, Psyrri A, Gogas H, Papadimitriou C. Neoadjuvant treatment in ovarian cancer: new perspectives, new challenges. Front Oncol. 2022;12:820128. https:\/\/doi.org\/10.3389\/fonc.2022.820128.","journal-title":"Front Oncol"},{"key":"10_CR88","doi-asserted-by":"publisher","first-page":"175883592311731","DOI":"10.1177\/17588359231173183","volume":"15","author":"H Hockings","year":"2023","unstructured":"Hockings H, Miller RE. The role of PARP inhibitor combination therapy in ovarian cancer. Ther Adv Med Oncol. 2023;15:17588359231173183. https:\/\/doi.org\/10.1177\/17588359231173183.","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"10_CR89","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.ygyno.2021.05.018","volume":"162","author":"A Alvarez Secord","year":"2021","unstructured":"Alvarez Secord A, O\u2019Malley DM, Sood AK, Westin SN, Liu JF. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: a review. Gynecol Oncol. 2021;162(2):482\u201395. https:\/\/doi.org\/10.1016\/j.ygyno.2021.05.018.","journal-title":"Gynecol Oncol"},{"issue":"30","key":"10_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.23.00529","volume":"41","author":"JE Kurtz","year":"2023","unstructured":"Kurtz JE, Lauraine EP, Oaknin A, Leither K, Cibula D, Denys H. Atezolizumab combined with bevacizumab and platinum-based therapy for platinum-sensitive ovarian cancer: placebo-controlled randomized phase III ATALANTE\/ENGOT-ov29 trial. J Clin Oncol. 2023;41(30):1\u201317. https:\/\/doi.org\/10.1200\/JCO.23.00529.","journal-title":"J Clin Oncol"},{"key":"10_CR91","doi-asserted-by":"publisher","first-page":"117955492199628","DOI":"10.1177\/1179554921996288","volume":"15","author":"Z Wu","year":"2021","unstructured":"Wu Z, Cui P, Tao H, Zhang S, Ma J, Liu Z, Wang J, Qian Y, Chen S, Huang Z, Zheng X, Huang D, Hu Y. The synergistic effect of PARP inhibitors and immune checkpoint inhibitors. Clin Med Insights Oncol. 2021;15:1179554921996288. https:\/\/doi.org\/10.1177\/1179554921996288.","journal-title":"Clin Med Insights Oncol"},{"key":"10_CR92","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.799957","volume":"11","author":"L Wen","year":"2021","unstructured":"Wen L, Tong F, Zhang R, Chen L, Huang Y, Dong X. The research progress of PD-1\/PD-L1 inhibitors enhancing radiotherapy efficacy. Front Oncol. 2021;11:799957. https:\/\/doi.org\/10.3389\/fonc.2021.799957.","journal-title":"Front Oncol"},{"issue":"4","key":"10_CR93","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/ijgc-2022-003941","volume":"33","author":"A Andrikopoulou","year":"2023","unstructured":"Andrikopoulou A, Liontos M, Skafida E, Koutsoukos K, Apostolidou K, Kaparelou M, Rouvalis A, Bletsa G, Dimopoulos MA, Zagouri F. Pembrolizumab in combination with bevacizumab and oral cyclophosphamide in heavily pre-treated platinum-resistant ovarian cancer. Int J Gynecol Cancer. 2023;33(4):571\u20136. https:\/\/doi.org\/10.1136\/ijgc-2022-003941.","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"10_CR94","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","volume":"21","author":"SM Domchek","year":"2020","unstructured":"Domchek SM, Postel-Vinay S, Im SA, Park YH, Delord JP, Italiano A, Alexandre J, You B, Bastian S, Krebs MG, Wang D, Waqar SN, Lanasa M, Rhee J, Gao H, Rocher-Ros V, Jones EV, Gulati S, Coenen-Stass A, Kozarewa I, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study. Lancet Oncol. 2020;21(9):1155\u201364. https:\/\/doi.org\/10.1016\/S1470-2045(20)30324-7.","journal-title":"Lancet Oncol"},{"issue":"16","key":"10_CR95","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1158\/1078-0432.CCR-20-0056","volume":"26","author":"EJ Lampert","year":"2020","unstructured":"Lampert EJ, Zimmer A, Padget M, Cimino-Mathews A, Nair JR, Liu Y, Swisher EM, Hodge JW, Nixon AB, Nichols E, Bagheri MH, Levy E, Radke MR, Lipkowitz S, Annunziata CM, Taube JM, Steinberg SM, Lee JM. Combination of PARP inhibitor Olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study. Clin Cancer Res. 2020;26(16):4268\u201379. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0056.","journal-title":"Clin Cancer Res"},{"key":"10_CR96","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.617335","volume":"11","author":"Y Lei","year":"2021","unstructured":"Lei Y, Li X, Huang Q, Zheng X, Liu M. Progress and challenges of predictive biomarkers for immune checkpoint blockade. Front Oncol. 2021;11:617335. https:\/\/doi.org\/10.3389\/fonc.2021.617335.","journal-title":"Front Oncol"},{"key":"10_CR97","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","volume":"18","author":"X Jiang","year":"2019","unstructured":"Jiang X, Wang J, Deng X, et al. Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18:10. https:\/\/doi.org\/10.1186\/s12943-018-0928-4.","journal-title":"Mol Cancer"},{"key":"10_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116203","volume":"171","author":"J-W Cui","year":"2024","unstructured":"Cui J-W, Li Y, Yang Y, Yang H-K, Dong J-M, Xiao Z-H, et al. A tumor immunotherapy resistance: revealing the mechanism of PD-1\/PD-L1-mediated tumor immune escape. Biomed Pharmacother. 2024;171:116203. https:\/\/doi.org\/10.1016\/j.biopha.2024.116203.","journal-title":"Biomed Pharmacother"},{"key":"10_CR99","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/s41598-019-57218-9","volume":"10","author":"S Hwang","year":"2020","unstructured":"Hwang S, Kwon AY, Jeong JY, et al. Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer. Sci Rep. 2020;10:643. https:\/\/doi.org\/10.1038\/s41598-019-57218-9.","journal-title":"Sci Rep"},{"issue":"5","key":"10_CR100","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","volume":"32","author":"DJ McGrail","year":"2021","unstructured":"McGrail DJ, Pili\u00e9 PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Lim B, Ueno NT, Litton JK, Ferrarotto R, Chang JT, Moulder SL, Lin SY. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021;32(5):661\u201372. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.006.","journal-title":"Ann Oncol"},{"key":"10_CR101","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12935-019-1091-8","volume":"20","author":"K Li","year":"2020","unstructured":"Li K, Luo H, Huang L, et al. Microsatellite instability: a review of what the oncologist should know. Cancer Cell Int. 2020;20:16. https:\/\/doi.org\/10.1186\/s12935-019-1091-8.","journal-title":"Cancer Cell Int"},{"issue":"2","key":"10_CR102","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3390\/jpm13020284","volume":"13","author":"A Mangogna","year":"2023","unstructured":"Mangogna A, Munari G, Pepe F, Maffii E, Giampaolino P, Ricci G, Fassan M, Malapelle U, Biffi S. Homologous recombination deficiency in ovarian cancer: from the biological rationale to current diagnostic approaches. J Pers Med. 2023;13(2):284. https:\/\/doi.org\/10.3390\/jpm13020284.","journal-title":"J Pers Med"},{"key":"10_CR103","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s40364-021-00333-5","volume":"9","author":"Z Hao","year":"2021","unstructured":"Hao Z, Li R, Wang Y, et al. Landscape of myeloid-derived suppressor cell in tumor immunotherapy. Biomark Res. 2021;9:77. https:\/\/doi.org\/10.1186\/s40364-021-00333-5.","journal-title":"Biomark Res"},{"issue":"6","key":"10_CR104","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.564","volume":"5","author":"H Wang","year":"2024","unstructured":"Wang H, Zhang Y, Zhang H, Cao H, Mao J, Chen X, Wang L, Zhang N, Luo P, Xue J, Qi X, Dong X, Liu G, Cheng Q. Liquid biopsy for human cancer: cancer screening, monitoring, and treatment. MedComm. 2024;5(6):e564. https:\/\/doi.org\/10.1002\/mco2.564.","journal-title":"MedComm"},{"issue":"12","key":"10_CR105","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.3390\/cancers15123205","volume":"15","author":"V Baev","year":"2023","unstructured":"Baev V, Koppers-Lalic D, Costa-Silva B. Liquid biopsy: current status and future perspectives. Cancer. 2023;15(12):3205. https:\/\/doi.org\/10.3390\/cancers15123205.","journal-title":"Cancer"},{"issue":"9","key":"10_CR106","doi-asserted-by":"publisher","first-page":"4802","DOI":"10.3390\/ijms22094802","volume":"22","author":"YI Nussbaum","year":"2021","unstructured":"Nussbaum YI, Manjunath Y, Suvilesh KN, Warren WC, Shyu CR, Kaifi JT, Ciorba MA, Mitchem JB. Current and prospective methods for assessing anti-tumor immunity in colorectal cancer. Int J Mol Sci. 2021;22(9):4802. https:\/\/doi.org\/10.3390\/ijms22094802.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189106","volume":"1879","author":"P Garg","year":"2024","unstructured":"Garg P, Krishna M, Subbalakshmi AR, Ramisetty S, Mohanty A, Kulkarni P, Horne D, Salgia R, Singhal SS. Emerging biomarkers and molecular targets for precision medicine in cervical cancer. Biochim Biophys Acta Rev Cancer. 2024;1879(3):189106. https:\/\/doi.org\/10.1016\/j.bbcan.2024.189106.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10_CR108","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","volume":"18","author":"S Qin","year":"2019","unstructured":"Qin S, Xu L, Yi M, et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18:155. https:\/\/doi.org\/10.1186\/s12943-019-1091-2.","journal-title":"Mol Cancer"},{"key":"10_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2019.101305","volume":"42","author":"E Ruffo","year":"2019","unstructured":"Ruffo E, Wu RC, Bruno TC, Workman CJ, Vignali DAA. Lymphocyte-activation gene 3 (LAG3): the next immune checkpoint receptor. Semin Immunol. 2019;42:101305. https:\/\/doi.org\/10.1016\/j.smim.2019.101305.","journal-title":"Semin Immunol"},{"issue":"11","key":"10_CR110","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1007\/s00262-023-03516-1","volume":"72","author":"N Sauer","year":"2023","unstructured":"Sauer N, Janicka N, Szlasa W, Skinderowicz B, Ko\u0142odzi\u0144ska K, Dwernicka W, O\u015bliz\u0142o M, Kulbacka J, Novickij V, Kar\u0142owicz-Bodalska K. TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors. Cancer Immunol Immunother. 2023;72(11):3405\u201325. https:\/\/doi.org\/10.1007\/s00262-023-03516-1.","journal-title":"Cancer Immunol Immunother"},{"key":"10_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.676181","volume":"12","author":"N Hosseinkhani","year":"2021","unstructured":"Hosseinkhani N, Derakhshani A, Shadbad MA, Argentiero A, Racanelli V, Kazemi T, Mokhtarzadeh A, Brunetti O, Silvestris N, Baradaran B. The role of V-domain Ig suppressor of T cell activation (VISTA) in cancer therapy: lessons learned and the road ahead. Front Immunol. 2021;12:676181. https:\/\/doi.org\/10.3389\/fimmu.2021.676181.","journal-title":"Front Immunol"},{"key":"10_CR112","doi-asserted-by":"publisher","first-page":"1426050","DOI":"10.3389\/fimmu.2024.1426050","volume":"15","author":"L Zhou","year":"2024","unstructured":"Zhou L, Duan Y, Fu K, Zhang M, Li K, Yin R. The role of B7-H4 in ovarian cancer immunotherapy: current status, challenges, and perspectives. Front Immunol. 2024;15:1426050. https:\/\/doi.org\/10.3389\/fimmu.2024.1426050.","journal-title":"Front Immunol"},{"issue":"7","key":"10_CR113","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.trecan.2020.02.003","volume":"6","author":"J Cao","year":"2020","unstructured":"Cao J, Yan Q. Cancer epigenetics, tumor immunity, and immunotherapy. Trends Cancer. 2020;6(7):580\u201392. https:\/\/doi.org\/10.1016\/j.trecan.2020.02.003.","journal-title":"Trends Cancer"},{"key":"10_CR114","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.809761","volume":"13","author":"Z Liu","year":"2022","unstructured":"Liu Z, Ren Y, Weng S, Xu H, Li L, Han X. A new trend in cancer treatment: the combination of epigenetics and immunotherapy. Front Immunol. 2022;13:809761. https:\/\/doi.org\/10.3389\/fimmu.2022.809761.","journal-title":"Front Immunol"},{"issue":"1","key":"10_CR115","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/cancers14010066","volume":"14","author":"E Borcoman","year":"2022","unstructured":"Borcoman E, Kamal M, Marret G, Dupain C, Castel-Ajgal Z, Le Tourneau C. HDAC inhibition to prime immune checkpoint inhibitors. Cancer. 2022;14(1):66. https:\/\/doi.org\/10.3390\/cancers14010066.","journal-title":"Cancer"},{"issue":"1","key":"10_CR116","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01316-8","volume":"20","author":"L Xia","year":"2021","unstructured":"Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N, Yi P, Tang L, Pan Q, Rao S, Liang J, Tang Y, Su M, Luo X, Yang Y, Shi Y, Wang H, Zhou Y, Liao Q. The cancer metabolic reprogramming and immune response. Mol Cancer. 2021;20(1):28. https:\/\/doi.org\/10.1186\/s12943-021-01316-8.","journal-title":"Mol Cancer"},{"key":"10_CR117","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.800630","volume":"12","author":"X Song","year":"2021","unstructured":"Song X, Si Q, Qi R, Liu W, Li M, Guo M, Wei L, Yao Z. Indoleamine 2,3-dioxygenase 1: a promising therapeutic target in malignant tumor. Front Immunol. 2021;12:800630. https:\/\/doi.org\/10.3389\/fimmu.2021.800630.","journal-title":"Front Immunol"},{"key":"10_CR118","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.semcancer.2019.12.019","volume":"65","author":"S Gomez","year":"2020","unstructured":"Gomez S, Tabernacki T, Kobyra J, Roberts P, Chiappinelli KB. Combining epigenetic and immune therapy to overcome cancer resistance. Semin Cancer Biol. 2020;65:99\u2013113. https:\/\/doi.org\/10.1016\/j.semcancer.2019.12.019.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"10_CR119","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.annonc.2023.10.125","volume":"35","author":"A Prelaj","year":"2024","unstructured":"Prelaj A, Miskovic V, Zanitti M, Trovo F, Genova C, Viscardi G, Rebuzzi SE, Mazzeo L, Provenzano L, Kosta S, Favali M, Spagnoletti A, Castelo-Branco L, Dolezal J, Pearson AT, Lo Russo G, Proto C, Ganzinelli M, Giani C, Ambrosini E, Pedrocchi ALG. Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review. Ann Oncol. 2024;35(1):29\u201365. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.125.","journal-title":"Ann Oncol"},{"issue":"6","key":"10_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.189026","volume":"1878","author":"P Garg","year":"2023","unstructured":"Garg P, Mohanty A, Ramisetty S, Kulkarni P, Horne D, Pisick E, Salgia R, Singhal SS. Artificial intelligence and allied subsets in early detection and preclusion of gynecological cancers. Biochim Biophys Acta Rev Cancer. 2023;1878(6):189026. https:\/\/doi.org\/10.1016\/j.bbcan.2023.189026.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"12","key":"10_CR121","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s43588-022-00377-z","volume":"2","author":"JD Butner","year":"2022","unstructured":"Butner JD, Dogra P, Chung C, Pasqualini R, Arap W, Lowengrub J, Cristini V, Wang Z. Mathematical modeling of cancer immunotherapy for personalized clinical translation. Nat Comput Sci. 2022;2(12):785\u201396. https:\/\/doi.org\/10.1038\/s43588-022-00377-z.","journal-title":"Nat Comput Sci"},{"issue":"22","key":"10_CR122","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.3390\/cancers16223884","volume":"16","author":"P Garg","year":"2024","unstructured":"Garg P, Singhal G, Kulkarni P, Horne D, Salgia R, Singhal SS. Artificial intelligence-driven computational approaches in the development of anticancer drugs. Cancer. 2024;16(22):3884. https:\/\/doi.org\/10.3390\/cancers16223884.","journal-title":"Cancer"},{"key":"10_CR123","doi-asserted-by":"publisher","first-page":"1054231","DOI":"10.3389\/fonc.2022.1054231","volume":"12","author":"Y Cai","year":"2023","unstructured":"Cai Y, Chen R, Gao S, Li W, Liu Y, Su G, Song M, Jiang M, Jiang C, Zhang X. Artificial intelligence applied in neoantigen identification facilitates personalized cancer immunotherapy. Front Oncol. 2023;12:1054231. https:\/\/doi.org\/10.3389\/fonc.2022.1054231.","journal-title":"Front Oncol"},{"issue":"1","key":"10_CR124","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/clinchem\/hvad196","volume":"70","author":"S Foser","year":"2024","unstructured":"Foser S, Maiese K, Digumarthy SR, Puig-Butille JA, Rebhan C. Looking to the future of early detection in cancer: liquid biopsies, imaging, and artificial intelligence. Clin Chem. 2024;70(1):27\u201332. https:\/\/doi.org\/10.1093\/clinchem\/hvad196.","journal-title":"Clin Chem"},{"issue":"24","key":"10_CR125","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.21037\/atm-20-4499","volume":"8","author":"NC Demircan","year":"2020","unstructured":"Demircan NC, Boussios S, Tasci T, \u00d6zt\u00fcrk MA. Current and future immunotherapy approaches in ovarian cancer. Ann Transl Med. 2020;8(24):1714. https:\/\/doi.org\/10.21037\/atm-20-4499.","journal-title":"Ann Transl Med"},{"key":"10_CR126","doi-asserted-by":"publisher","first-page":"26617","DOI":"10.1038\/s41598-024-77630-0","volume":"14","author":"T Wang","year":"2024","unstructured":"Wang T, Tian L, Wei B, et al. Effect of fibroblast heterogeneity on prognosis and drug resistance in high-grade serous ovarian cancer. Sci Rep. 2024;14:26617. https:\/\/doi.org\/10.1038\/s41598-024-77630-0.","journal-title":"Sci Rep"},{"key":"10_CR127","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.3390\/cancers15123220","volume":"15","author":"I Colombo","year":"2023","unstructured":"Colombo I, Karakasis K, Suku S, Oza AM. Chasing immune checkpoint inhibitors in ovarian cancer: novel combinations and biomarker discovery. Cancer. 2023;15:3220. https:\/\/doi.org\/10.3390\/cancers15123220.","journal-title":"Cancer"},{"key":"10_CR128","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1200\/EDBK_359650","volume":"42","author":"YT Shih","year":"2022","unstructured":"Shih YT, Pan IW, Teich N. Global challenges in access to and implementation of precision oncology: the health care manager and health economist perspective. Proc Am Soc Clin Oncol. 2022;42:429\u201337. https:\/\/doi.org\/10.1200\/EDBK_359650.","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"4","key":"10_CR129","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707\u201323. https:\/\/doi.org\/10.1016\/j.cell.2017.01.017.","journal-title":"Cell"},{"issue":"4","key":"10_CR130","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1158\/1078-0432.CCR-14-1860","volume":"21","author":"GL Beatty","year":"2015","unstructured":"Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2015;21(4):687\u201392. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1860.","journal-title":"Clin Cancer Res"},{"key":"10_CR131","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40164-022-00356-0","volume":"11","author":"M Dai","year":"2022","unstructured":"Dai M, Liu M, Yang H, et al. New insights into epigenetic regulation of resistance to PD-1\/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities. Exp Hematol Oncol. 2022;11:101. https:\/\/doi.org\/10.1186\/s40164-022-00356-0.","journal-title":"Exp Hematol Oncol"},{"key":"10_CR132","doi-asserted-by":"publisher","first-page":"1197364","DOI":"10.3389\/fimmu.2023.1197364","volume":"14","author":"B Ibis","year":"2023","unstructured":"Ibis B, Aliazis K, Cao C, Yenyuwadee S, Boussiotis VA. Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases. Front Immunol. 2023;14:1197364. https:\/\/doi.org\/10.3389\/fimmu.2023.1197364.","journal-title":"Front Immunol"},{"issue":"17","key":"10_CR133","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, National Comprehensive Cancer Network. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714\u201368. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385.","journal-title":"J Clin Oncol"},{"key":"10_CR134","doi-asserted-by":"publisher","first-page":"1483454","DOI":"10.3389\/fonc.2024.1483454","volume":"14","author":"X Yin","year":"2024","unstructured":"Yin X, Song Y, Deng W, Blake N, Luo X, Meng J. Potential predictive biomarkers in antitumor immunotherapy: navigating the future of antitumor treatment and immune checkpoint inhibitor efficacy. Front Oncol. 2024;14:1483454. https:\/\/doi.org\/10.3389\/fonc.2024.1483454.","journal-title":"Front Oncol"},{"key":"10_CR135","doi-asserted-by":"publisher","first-page":"5245034","DOI":"10.1155\/2019\/5245034","volume":"2019","author":"S Joshi","year":"2019","unstructured":"Joshi S, Durden DL. Combinatorial approach to improve cancer immunotherapy: rational drug design strategy to simultaneously hit multiple targets to kill tumor cells and to activate the immune system. J Oncol. 2019;2019:5245034. https:\/\/doi.org\/10.1155\/2019\/5245034.","journal-title":"J Oncol"},{"issue":"11","key":"10_CR136","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.3390\/cancers13112761","volume":"13","author":"A Chianese","year":"2021","unstructured":"Chianese A, Santella B, Ambrosino A, Stelitano D, Rinaldi L, Galdiero M, Zannella C, Franci G. Oncolytic viruses in combination therapeutic approaches with epigenetic modulators: past, present, and future perspectives. Cancer. 2021;13(11):2761. https:\/\/doi.org\/10.3390\/cancers13112761.","journal-title":"Cancer"},{"key":"10_CR137","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.998222","volume":"12","author":"J Liao","year":"2023","unstructured":"Liao J, Li X, Gan Y, Han S, Rong P, Wang W, Li W, Zhou L. Artificial intelligence assists precision medicine in cancer treatment. Front Oncol. 2023;12:998222. https:\/\/doi.org\/10.3389\/fonc.2022.998222.","journal-title":"Front Oncol"},{"key":"10_CR138","doi-asserted-by":"publisher","first-page":"1455163","DOI":"10.3389\/fimmu.2024.1455163","volume":"15","author":"E Ponterio","year":"2024","unstructured":"Ponterio E, Haas TL, De Maria R. Oncolytic virus and CAR-T cell therapy in solid tumors. Front Immunol. 2024;15:1455163. https:\/\/doi.org\/10.3389\/fimmu.2024.1455163.","journal-title":"Front Immunol"},{"issue":"1","key":"10_CR139","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3390\/cancers16010103","volume":"16","author":"T Liu","year":"2023","unstructured":"Liu T, Yu J, Gao Y, Ma X, Jiang S, Gu Y, Ming WK. Prophylactic interventions for hereditary breast and ovarian cancer risks and mortality in BRCA1\/2 carriers. Cancer. 2023;16(1):103. https:\/\/doi.org\/10.3390\/cancers16010103.","journal-title":"Cancer"},{"issue":"3","key":"10_CR140","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1124\/jpet.118.254979","volume":"370","author":"B Corradetti","year":"2019","unstructured":"Corradetti B, Pisano S, Conlan RS, Ferrari M. Nanotechnology and immunotherapy in ovarian cancer: tracing new landscapes. J Pharmacol Exp Ther. 2019;370(3):636\u201346. https:\/\/doi.org\/10.1124\/jpet.118.254979.","journal-title":"J Pharmacol Exp Ther"},{"key":"10_CR141","doi-asserted-by":"publisher","first-page":"1416555","DOI":"10.3389\/fphar.2024.1416555","volume":"15","author":"M Satora","year":"2024","unstructured":"Satora M, Ku\u0142ak K, Zaremba B, Grunwald A, \u015awiechowska-Starek P, Tarkowski R. New hopes and promises in the treatment of ovarian cancer focusing on targeted treatment\u2014a narrative review. Front Pharmacol. 2024;15:1416555. https:\/\/doi.org\/10.3389\/fphar.2024.1416555.","journal-title":"Front Pharmacol"},{"issue":"9","key":"10_CR142","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.3390\/biomedicines12092158","volume":"12","author":"R Ghemrawi","year":"2024","unstructured":"Ghemrawi R, Abuamer L, Kremesh S, Hussien G, Ahmed R, Mousa W, Khoder G, Khair M. Revolutionizing cancer treatment: recent advances in immunotherapy. Biomedicine. 2024;12(9):2158. https:\/\/doi.org\/10.3390\/biomedicines12092158.","journal-title":"Biomedicine"},{"issue":"1","key":"10_CR143","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/biomedicines12010217","volume":"12","author":"S Adhikary","year":"2024","unstructured":"Adhikary S, Pathak S, Palani V, Acar A, Banerjee A, Al-Dewik NI, Essa MM, Mohammed SGAA, Qoronfleh MW. Current technologies and future perspectives in immunotherapy towards a clinical oncology approach. Biomedicine. 2024;12(1):217. https:\/\/doi.org\/10.3390\/biomedicines12010217.","journal-title":"Biomedicine"}],"container-title":["Cancer Treatment and Research","Immunotherapies in Solid Tumors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-97242-3_10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:32:20Z","timestamp":1778880740000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-97242-3_10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9783031972416","9783031972423"],"references-count":143,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-97242-3_10","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-3-031-97242-3","asserted-by":"object"}]},"ISSN":["0927-3042","2509-8497"],"issn-type":[{"value":"0927-3042","type":"print"},{"value":"2509-8497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"23 August 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}